Starling Oncology, Inc. (STLNW) Free cash flow 2020–2025
Starling Oncology, Inc. (STLNW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$27.8MFY2025 · since FY2020: -$686,000 → -$27.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.8M | +8.4% |
| FY2024 | -$30.3M | +25.8% |
| FY2023 | -$40.9M | +39.2% |
| FY2022 | -$67.3M | -89.4% |
| FY2021 | -$35.5M | -5078.9% |
| FY2020 | -$686,000 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Operating cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →